XFOR Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$1.60 |
| 52 Week Low | US$0.26 |
| Beta | 0.39 |
| 11 Month Change | -25.81% |
| 3 Month Change | -51.59% |
| 1 Year Change | -51.68% |
| 33 Year Change | -92.14% |
| 5 Year Change | -96.52% |
| Change since IPO | -97.58% |
Recent News & Updates
Recent updates
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16X4 Pharmaceuticals EPS misses by $0.12
Nov 05Shareholder Returns
| XFOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 32.7% | -7.5% | -1.2% |
| 1Y | -51.7% | 14.1% | 30.4% |
Return vs Industry: XFOR underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: XFOR underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| XFOR volatility | |
|---|---|
| XFOR Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XFOR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XFOR's weekly volatility has increased from 17% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 143 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| XFOR fundamental statistics | |
|---|---|
| Market cap | US$62.76m |
| Earnings (TTM) | -US$16.76m |
| Revenue (TTM) | US$1.12m |
55.9x
P/S Ratio-3.7x
P/E RatioIs XFOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XFOR income statement (TTM) | |
|---|---|
| Revenue | US$1.12m |
| Cost of Revenue | US$495.00k |
| Gross Profit | US$628.00k |
| Other Expenses | US$17.39m |
| Earnings | -US$16.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 55.92% |
| Net Profit Margin | -1,492.34% |
| Debt/Equity Ratio | 126.2% |
How did XFOR perform over the long term?
See historical performance and comparison